title: Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia.
abstract: Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4/CD8 ratio decreased and the CD8 T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.
authors.affiliation: aINSERM, U1135, CIMI bSorbonne Universités, UPMC Univ Paris cINSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique dService des maladies infectieuses et tropicales eDépartement d'Immunologie fAP-HP, Laboratoire de Virologie, Groupe hospitalier Pitié Salpêtrière gSorbonne Universités, UPMC Univ Paris 06 hINSERM, UMR-S 938, CDR Saint Antoine iAP-HP, Département de Biochimie et Hormonologie, Groupe Hospitalier Tenon jSorbonne Universités, UPMC Univ Paris 06, CIMI, Paris, France. *Dr Christine Katlama and Dr Amélie Guihot contributed equally to the writing of this article.
authors.forename: Laure
authors.initials: L
authors.lastname: Campillo-Gimenez
authors.forename: Lambert
authors.initials: L
authors.lastname: Assoumou
authors.forename: Marc-Antoine
authors.initials: MA
authors.lastname: Valantin
authors.forename: Priyadharshini
authors.initials: P
authors.lastname: Pajanirassa
authors.forename: Juliette
authors.initials: J
authors.lastname: Villemonteix
authors.forename: Cathia
authors.initials: C
authors.lastname: Soulié
authors.forename: Anne-Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Capeau
authors.forename: Brigitte
authors.initials: B
authors.lastname: Autran
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Amélie
authors.initials: A
authors.lastname: Guihot
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003510:Cyclohexanes / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load; D014766:Viremia
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D012367:RNA, Viral; D014230:Triazoles; D000068898:Raltegravir Potassium; D000077592:Maraviroc